• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

    56.96 -1.90 (-3.23%)
    Streaming Delayed Price Updated: 1:41 PM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about State Street SPDR S&P Pharmaceuticals ETF

    < Previous 1 2 Next >
    News headline image
    ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
    Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million. 
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Why Did CANF Stock Soar 40% In Pre-Market Today? ↗
    The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint. 
    Via Stocktwits
    News headline image
    TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗
    The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint. 
    Via Stocktwits
    Topics Workforce
    News headline image
    FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗
    Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments. 
    Via Stocktwits
    Topics ETFs Government
    Why Did AQST Stock Plunge 40% In Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗
    Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin. 
    Via Stocktwits
    News headline image
    Why Did CRMD Stock Crash 28% Today? ↗
    CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data. 
    Via Stocktwits
    News headline image
    Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗
    Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them." 
    Via Benzinga
    News headline image
    Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
    The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
    Via Benzinga
    Topics ETFs
    News headline image
    Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗
    President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Pharma Tariffs Back In Spotlight On New Trump Threat ↗
    President Donald Trump threatened 100% tariffs on some drug imports. 
    Via Investor's Business Daily
    Topics ETFs Government World Trade
    News headline image
    Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗
    Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices. 
    Via Benzinga
    News headline image
    Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗
    The tariffs will impact products imported from Europe, the Trump administration said late Thursday. 
    Via Investor's Business Daily
    Topics ETFs Government Intellectual Property
    News headline image
    Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗
    Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation. 
    Via Benzinga
    News headline image
    Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)
    In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at... 
    Via MarketMinute
    Topics ETFs Economy
    News headline image
    Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗
    Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗
    Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗
    A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
    Via Benzinga
    News headline image
    Trump Sparks New Chapter In Transatlantic Trade War: What The US Buys From Europe ↗
    Trump announced 50% tariffs on all EU imports starting June 1, citing high trade deficits and unfair barriers. Pharmaceutical products and cars most exposed. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work ↗
    The Trump administration unveiled the first details Tuesday on how it plans to lower drug prices "drastically" in the U.S. 
    Via Investor's Business Daily
    Topics ETFs Government
    News headline image
    Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗
    Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket. 
    Via Benzinga
    Topics Government
    News headline image
    Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗
    Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
    Via Benzinga
    Topics ETFs Government
    News headline image
    Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗
    Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
    Via Stocktwits
    Topics Government Intellectual Property Lawsuit
    News headline image
    ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗
    Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
    Via Benzinga
    Topics ETFs
    News headline image
    Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗
    Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? ↗
    Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain. 
    Via Benzinga
    Topics World Trade
    News headline image
    Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In ↗
    The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected. 
    Via Stocktwits
    News headline image
    Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 ↗
    CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key... 
    Via Stocktwits
    News headline image
    Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027 ↗
    Perrigo Company shares surged after issuing financial targets for 2025 & 2025-2027 on investor day. Expect sales growth, EPS, and margin expansion. 'Three-S' plan will enhance cash flow & shareholder... 
    Via Benzinga
    News headline image
    Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗
    Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally. 
    Via Benzinga
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.